Glucagon-like peptide-1 receptor agonists are a viable option for the prevention of Alzheimer’s disease (AD) but the mechanisms of this potential disease modifying action are unclear. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.